Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury.

Elmorsy EA, Amer MM, Hamad RS, Abdel-Hamed MR, Farrag AA, Alorini M, Khodeir MM, Ali MAM, Alhowail AH, Mohamed EA, Alsalloom AA, Alsaykhan H and 5 more

Show all authors

Alsoqih NS, Ata HS, Sameh A, Chaudhary AA, Saber S

Tissue & cell2 Apr 2026Cited by 1 (Europe PMC)

PMID41934921DOI10.1016/j.tice.2026.103514PepBankPUB-41934921

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In experimental acute lung injury after lipopolysaccharide, elamipretide predominantly improved redox status.
In plain wordsIn an animal lung injury model, elamipretide mainly improved the balance of oxidative stress.
Peptide
Elamipretide (SS-31)
Outcome
Not applicableRedox status
Study
n: not reported in source
LPS-induced acute lung injury
Outcome group
Inflammation markers · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
ELM predominantly improved redox status
1 context sentence(design, population, supporting numbers)
Summary · context
At 24 h post intratracheal lipopolysaccharide, lung architecture was assessed histologically, and BALF and lung tissue were analyzed for barrier and cytolytic injury
Report a problemFND-4193492101
02AnimalAnimal study (in vivo)Mechanism
In experimental acute lung injury after lipopolysaccharide, elamipretide reduced mitochondrial leak.
In plain wordsIn an animal lung injury model, elamipretide reduced the leak of mitochondrial material.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseMitochondrial leak
Study
n: not reported in source
LPS-induced acute lung injury
Outcome group
Mitochondrial function · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
ELM predominantly improved redox status and reduced mitochondrial leak
1 context sentence(design, population, supporting numbers)
Summary · context
At 24 h post intratracheal lipopolysaccharide, lung architecture was assessed histologically, and BALF and lung tissue were analyzed for barrier and cytolytic injury
Report a problemFND-4193492102

Studies that did not test the peptide alone4

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In experimental acute lung injury, combined elamipretide and H151 gave the greatest improvement in lung histology.
In plain wordsIn an animal lung injury model, elamipretide with H151 gave the best improvement in lung tissue structure.
Peptide
Elamipretide (SS-31)
Outcome
Not applicableLung histology
Study
n: not reported in source
LPS-induced acute lung injury
Outcome group
Inflammation markers · Respiratory
Source sentences
Summary
Notably, combined ELM+H151 produced the most comprehensive protection, yielding the greatest improvement in lung histology together with reductions in barrier disruption, inflammatory cellular infiltration, and downstream signaling outputs.
1 context sentence(design, population, supporting numbers)
Summary · context
At 24 h post intratracheal lipopolysaccharide, lung architecture was assessed histologically, and BALF and lung tissue were analyzed for barrier and cytolytic injury
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4193492103
04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In experimental acute lung injury, combined elamipretide and H151 reduced barrier disruption.
In plain wordsIn an animal lung injury model, elamipretide with H151 reduced damage to the lung barrier.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseBarrier disruption
Study
n: not reported in source
LPS-induced acute lung injury
Outcome group
Inflammation markers · Respiratory
Source sentences
Summary
Notably, combined ELM+H151 produced the most comprehensive protection, yielding the greatest improvement in lung histology together with reductions in barrier disruption, inflammatory cellular infiltration, and downstream signaling outputs.
1 context sentence(design, population, supporting numbers)
Summary · context
At 24 h post intratracheal lipopolysaccharide, lung architecture was assessed histologically, and BALF and lung tissue were analyzed for barrier and cytolytic injury
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4193492104
05AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In experimental acute lung injury, combined elamipretide and H151 reduced inflammatory cellular infiltration.
In plain wordsIn an animal lung injury model, elamipretide with H151 reduced the inflammatory cells in the lung.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseInflammatory cellular infiltration
Study
n: not reported in source
LPS-induced acute lung injury
Outcome group
Inflammation markers · Respiratory
Source sentences
Summary
Notably, combined ELM+H151 produced the most comprehensive protection, yielding the greatest improvement in lung histology together with reductions in barrier disruption, inflammatory cellular infiltration, and downstream signaling outputs.
1 context sentence(design, population, supporting numbers)
Summary · context
At 24 h post intratracheal lipopolysaccharide, lung architecture was assessed histologically, and BALF and lung tissue were analyzed for barrier and cytolytic injury
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4193492105
06AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Mechanism
In experimental acute lung injury, combined elamipretide and H151 reduced downstream signaling outputs.
In plain wordsIn an animal lung injury model, elamipretide with H151 reduced inflammation signals.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseDownstream signaling outputs
Study
n: not reported in source
LPS-induced acute lung injury
Outcome group
Inflammation markers · Respiratory
Source sentences
Summary
Notably, combined ELM+H151 produced the most comprehensive protection, yielding the greatest improvement in lung histology together with reductions in barrier disruption, inflammatory cellular infiltration, and downstream signaling outputs.
1 context sentence(design, population, supporting numbers)
Summary · context
At 24 h post intratracheal lipopolysaccharide, lung architecture was assessed histologically, and BALF and lung tissue were analyzed for barrier and cytolytic injury
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4193492106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.